CA
REGN icon

Calton & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Calton & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-329
Closed -$206K – 364
2020
Q2 		$206K Buy
+329
New +$187K 0.04% 302
2018
Q1 		– Sell
-94
Closed -$35K – 1062
2017
Q4 		$35K Buy
+94
New +$38.1K 0.01% 768

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Calton & Associates's REGN Position: Q3 2020 in Review

Calton & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 329 shares — an estimated $206K sold.

Calton & Associates first reported a position in REGN in Q4 2017 and held it in 2 quarters. The position peaked at $206K in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Calton & Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Calton & Associates sold 329 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $206K.
  • Calton & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Calton & Associates's Regeneron Pharmaceuticals position peaked at $206K in Q2 2020.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Calton & Associates's 13F filing for Q3 2020, filed 30 Oct 2020.